Yuan S, Shi H, Cui Y, Liu Y, Cai M, Huang Y
Sci Rep. 2024; 14(1):29900.
PMID: 39622849
PMC: 11611886.
DOI: 10.1038/s41598-024-78978-z.
Ahmad R, Haque M
Cureus. 2024; 16(10):e71730.
PMID: 39421288
PMC: 11486535.
DOI: 10.7759/cureus.71730.
Mehta M, Shah J, Joshi U
Cureus. 2024; 16(10):e70768.
PMID: 39364176
PMC: 11448744.
DOI: 10.7759/cureus.70768.
Huang X, Li Z, Zhai Z, Wang Q, Wei R, Mo J
Diabetes Metab Syndr Obes. 2024; 17:1119-1130.
PMID: 38465347
PMC: 10924916.
DOI: 10.2147/DMSO.S447897.
Ho W, Chen H, Chen P, Liao T, Chang S, Chen Y
BMJ Open. 2024; 14(1):e079296.
PMID: 38272552
PMC: 10824018.
DOI: 10.1136/bmjopen-2023-079296.
Metabolic dysfunction-associated fatty liver disease in the elderly with diabetic foot ulcers: A longitudinal cohort study.
Zhang L, Lin Y, Huang X, Zhai Z, Wei R, Mo J
Int Wound J. 2023; 21(4):e14586.
PMID: 38102851
PMC: 10961876.
DOI: 10.1111/iwj.14586.
Sex-specific prevalence and risk factors of metabolic-associated fatty liver disease among 75,570 individuals in eastern China.
Chang M, Shao Z, Wei W, Shen P, Shen G
Front Endocrinol (Lausanne). 2023; 14:1241169.
PMID: 37822594
PMC: 10563804.
DOI: 10.3389/fendo.2023.1241169.
Pharmacological action of polysaccharides: a review.
Gao X, Ren C, Li L, Zhao H, Liu K, Zhuang M
Front Pharmacol. 2023; 14:1119224.
PMID: 37701035
PMC: 10494935.
DOI: 10.3389/fphar.2023.1119224.
Analysis of clinical features and identification of risk factors in patients with non-alcoholic fatty liver disease based on FibroTouch.
Liao Y, Liu L, Yang J, Zhou X, Teng X, Li Y
Sci Rep. 2023; 13(1):14812.
PMID: 37684380
PMC: 10491815.
DOI: 10.1038/s41598-023-41596-2.
Hypertriglyceridemic hyperapoB and the development and resolution of nonalcoholic fatty liver disease: a cohort study.
Wang Y, Kong L, Ye C, Dou C, Li M, Zhao Z
J Lipid Res. 2023; 64(8):100418.
PMID: 37481036
PMC: 10448465.
DOI: 10.1016/j.jlr.2023.100418.
Effect and Safety of Pioglitazone-Metformin Tablets in the Treatment of Newly Diagnosed Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease in Shaanxi Province: A Randomized, Double-Blinded, Double-Simulated Multicenter Study.
Jianfang F, Wanxia X, Xiling G, Jing X, Wenjuan Y, Jianrong L
J Diabetes Res. 2023; 2023:2044090.
PMID: 37305429
PMC: 10250100.
DOI: 10.1155/2023/2044090.
Association Between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review and Meta-Analysis.
Sun Q, Zhang T, Manji L, Liu Y, Chang Q, Zhao Y
Clin Epidemiol. 2023; 15:683-693.
PMID: 37305378
PMC: 10252946.
DOI: 10.2147/CLEP.S403314.
Association between triglyceride glucose-related markers and the risk of metabolic-associated fatty liver disease: a cross-sectional study in healthy Chinese participants.
Chang M, Shao Z, Shen G
BMJ Open. 2023; 13(5):e070189.
PMID: 37130686
PMC: 10163481.
DOI: 10.1136/bmjopen-2022-070189.
Prevalence of nonalcoholic fatty liver disease and the related risk factors among healthy adults: A cross-sectional study in Chongqing, China.
Kong L, Yang Y, Li H, Shan Y, Wang X, Shan X
Front Public Health. 2023; 11:1127489.
PMID: 37077190
PMC: 10108879.
DOI: 10.3389/fpubh.2023.1127489.
Dexmedetomidine improves DM-induced oxidative stress injury to protect liver function through Nrf2 pathway.
Zeng L, Zhao C, Cui C, Liu J, Wang Y, Zhang Y
Am J Transl Res. 2023; 15(3):1715-1729.
PMID: 37056865
PMC: 10086873.
Risk of subclinical atherosclerosis across metabolic transition in individuals with or without fatty liver disease: a prospective cohort study.
Xin Z, Huang J, Cao Q, Wang J, He R, Hou T
Nutr Metab (Lond). 2023; 20(1):15.
PMID: 36899397
PMC: 10007748.
DOI: 10.1186/s12986-023-00734-3.
PNPLA3 148M/M Is More Susceptible to Palmitic Acid-Induced Endoplasmic Reticulum Stress-Associated Apoptosis in HepG2 Cells.
Chen Y, Yan X, Wang T, Deng H, Deng X, Xu F
Int J Endocrinol. 2023; 2023:2872408.
PMID: 36825197
PMC: 9943609.
DOI: 10.1155/2023/2872408.
Combined CNN and Pixel Feature Image for Fatty Liver Ultrasound Image Classification.
Zhu H, Liu Y, Gao X, Zhang L
Comput Math Methods Med. 2022; 2022:9385734.
PMID: 36561737
PMC: 9767727.
DOI: 10.1155/2022/9385734.
Lower serum PRL is associated with the development of non-alcoholic fatty liver disease: a retrospective cohort study.
Xu P, Zhu Y, Ji X, Ma H, Zhang P, Bi Y
BMC Gastroenterol. 2022; 22(1):523.
PMID: 36526972
PMC: 9758822.
DOI: 10.1186/s12876-022-02619-w.
Investigating microRNAs to Explain the Link between Cholesterol Metabolism and NAFLD in Humans: A Systematic Review.
Konings M, Baumgartner S, Mensink R, Plat J
Nutrients. 2022; 14(23).
PMID: 36500981
PMC: 9738374.
DOI: 10.3390/nu14234946.